Embecta Corp. (EMBC)
NASDAQ: EMBC · Real-Time Price · USD
12.41
+0.44 (3.68%)
At close: May 12, 2025, 4:00 PM
12.18
-0.23 (-1.85%)
After-hours: May 12, 2025, 4:10 PM EDT
Embecta Revenue
Embecta had revenue of $259.00M in the quarter ending March 31, 2025, a decrease of -9.82%. This brings the company's revenue in the last twelve months to $1.08B, down -4.68% year-over-year. In the fiscal year ending September 30, 2024, Embecta had annual revenue of $1.12B with 0.21% growth.
Revenue (ttm)
$1.08B
Revenue Growth
-4.68%
P/S Ratio
0.67
Revenue / Employee
$514,048
Employees
2,100
Market Cap
725.27M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EMBC News
- 3 days ago - Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 3 days ago - embecta Announces Quarterly Cash Dividend - GlobeNewsWire
- 14 days ago - Embecta to host Analyst and Investor Day on May 22, 2025 - GlobeNewsWire
- 21 days ago - embecta to Report Fiscal Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations - GlobeNewsWire
- 2 months ago - Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour - Seeking Alpha
- 2 months ago - embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference - GlobeNewsWire